Abstract
Despite its importance in drug metabolism and disease susceptibility, CYP2D6 activity and genetic polymorphism have rarely been investigated in African American populations. In order to bridge this information gap, we examined the genotype and phenotype of the enzyme in 154 African American (AA) and 143 Caucasian (C) normal volunteers. As shown in Table 1, AAs are significantly more likely to possess*17 and*5, but less likely to have*4. Overall, the two groups were similar in their CYP2D6 activity as measured with the dextromethorphan as the probe (MR: 2.21±.78 for AAs; 2.11±.86 for Cs; t=1.02, NS). Two of 4 AAs and 6 of 7 Cs were classified as poor metabolizers (PMs) have two nonfunctioning alleles. CYP2D6 activity is determined by*17,*4*5 and age in AAs (R2=.33, F=18.8, p<.001) and by*4 and*XN Cs (R2=.14, F=10.8, p<.001). These results support previous findings of the importance of*17 in determining CYP2D6 activity in AAs. Table 1 Frequency of Key CYP2D6 Alleles in AAs and Cs %Alleles*2*3*4*5*10*17*NX AA 26.9 0.3 7.8 6.2 7.5 14.6 1.9 C 26.2 1.4 19.9 2.1 8.0 0.3 1.4.
| Original language | English (US) |
|---|---|
| Journal | Clinical Pharmacology and Therapeutics |
| Volume | 69 |
| Issue number | 2 |
| State | Published - 2001 |
Fingerprint
ASJC Scopus subject areas
- Pharmacology
Cite this
CYP2D6 gene polymorphism and enzyme activity in African Americans in southern California. / Wan, Yu-Jui Yvonne; Poland, R. E.; Ran, G.; Konishi, T.; Zheng, Y. P.; Lin, K. M.
In: Clinical Pharmacology and Therapeutics, Vol. 69, No. 2, 2001.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - CYP2D6 gene polymorphism and enzyme activity in African Americans in southern California
AU - Wan, Yu-Jui Yvonne
AU - Poland, R. E.
AU - Ran, G.
AU - Konishi, T.
AU - Zheng, Y. P.
AU - Lin, K. M.
PY - 2001
Y1 - 2001
N2 - Despite its importance in drug metabolism and disease susceptibility, CYP2D6 activity and genetic polymorphism have rarely been investigated in African American populations. In order to bridge this information gap, we examined the genotype and phenotype of the enzyme in 154 African American (AA) and 143 Caucasian (C) normal volunteers. As shown in Table 1, AAs are significantly more likely to possess*17 and*5, but less likely to have*4. Overall, the two groups were similar in their CYP2D6 activity as measured with the dextromethorphan as the probe (MR: 2.21±.78 for AAs; 2.11±.86 for Cs; t=1.02, NS). Two of 4 AAs and 6 of 7 Cs were classified as poor metabolizers (PMs) have two nonfunctioning alleles. CYP2D6 activity is determined by*17,*4*5 and age in AAs (R2=.33, F=18.8, p<.001) and by*4 and*XN Cs (R2=.14, F=10.8, p<.001). These results support previous findings of the importance of*17 in determining CYP2D6 activity in AAs. Table 1 Frequency of Key CYP2D6 Alleles in AAs and Cs %Alleles*2*3*4*5*10*17*NX AA 26.9 0.3 7.8 6.2 7.5 14.6 1.9 C 26.2 1.4 19.9 2.1 8.0 0.3 1.4.
AB - Despite its importance in drug metabolism and disease susceptibility, CYP2D6 activity and genetic polymorphism have rarely been investigated in African American populations. In order to bridge this information gap, we examined the genotype and phenotype of the enzyme in 154 African American (AA) and 143 Caucasian (C) normal volunteers. As shown in Table 1, AAs are significantly more likely to possess*17 and*5, but less likely to have*4. Overall, the two groups were similar in their CYP2D6 activity as measured with the dextromethorphan as the probe (MR: 2.21±.78 for AAs; 2.11±.86 for Cs; t=1.02, NS). Two of 4 AAs and 6 of 7 Cs were classified as poor metabolizers (PMs) have two nonfunctioning alleles. CYP2D6 activity is determined by*17,*4*5 and age in AAs (R2=.33, F=18.8, p<.001) and by*4 and*XN Cs (R2=.14, F=10.8, p<.001). These results support previous findings of the importance of*17 in determining CYP2D6 activity in AAs. Table 1 Frequency of Key CYP2D6 Alleles in AAs and Cs %Alleles*2*3*4*5*10*17*NX AA 26.9 0.3 7.8 6.2 7.5 14.6 1.9 C 26.2 1.4 19.9 2.1 8.0 0.3 1.4.
UR - http://www.scopus.com/inward/record.url?scp=33748966846&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33748966846&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:33748966846
VL - 69
JO - Clinical Pharmacology and Therapeutics
JF - Clinical Pharmacology and Therapeutics
SN - 0009-9236
IS - 2
ER -